Welcome Santo Therapeutics to SBC!
SBC is delighted to welcome Santo BioPharma to SBC Santo [...]
Nezar Clinical Services Joins SBC’s Seed Works
SBC is delighted to welcome Nezar Clinical Services as their [...]
Survey for mapping project aiming to advance commercialisation of UK life science products
SBC Partners with The Research and Development Society to [...]
Boehringer Ingelheim and Tessellate Bio partner to develop first-in-class precision treatments for people with hard-to-treat cancers
Ingelheim, Germany and Amsterdam, the Netherlands, 23 [...]
Catalyser applications now open!
Applications are now open for Catalyser 2025! Are you a [...]
SBC wins Best Performing R&D Facility for second year running at One Nucleus Awards
We're thrilled to share news that Stevenage Bioscience Catalyst has [...]
LifeArc Ventures is part of investor syndicate for Hillstar Bio who closes $67 million Series A financing round
Hillstar Bio closes $67 million Series A [...]
Blujepa (gepotidacin) approved by US FDA for treatment of uncomplicated urinary tract infections (uUTIs) in female adults and paediatric patients 12 years of age and older
Blujepa (gepotidacin) approved by US FDA for [...]
Job Vacancy: Facilities Officer
Stevenage Bioscience Catalyst (SBC) is looking for a Facilities Officer [...]
Santo Therapeutics Begins Clinical Trial Targeting NF2-Related Tumours
Santo Therapeutics Begins Clinical Trial Targeting NF2-Related Tumours Santo’s ST002 [...]
